European Medicines Agency recommends acoziborole for single-dose sleeping sickness treatment

news-medical.net

Acoziborole has received a positive opinion from the European Medicines Agency for a single-dose oral treatment for sleeping sickness. The treatment, for gambiense sleeping sickness in adults and adolescents, marks a significant advance over current multi-day or injectable therapies. This endorsement supports regulatory approval in the Democratic Republic of Congo and potential guideline revisions. Co-developed by DNDi and Sanofi, the medicine will be donated to the WHO and provided free to patients, aiming to aid sleeping sickness elimination efforts.


With a significance score of 4.1, this news ranks in the top 4.8% of today's 32010 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


European Medicines Agency recommends acoziborole for single-dose sleeping sickness treatment | News Minimalist